These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 19378378)
1. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Riedel G; Fadda P; McKillop-Smith S; Pertwee RG; Platt B; Robinson L Br J Pharmacol; 2009 Apr; 156(7):1154-66. PubMed ID: 19378378 [TBL] [Abstract][Full Text] [Related]
2. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes. Dennis I; Whalley BJ; Stephens GJ Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244 [TBL] [Abstract][Full Text] [Related]
3. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Järbe TU; DiPatrizio NV Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441 [TBL] [Abstract][Full Text] [Related]
4. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee RG Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291 [TBL] [Abstract][Full Text] [Related]
5. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647 [TBL] [Abstract][Full Text] [Related]
6. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Tallett AJ; Blundell JE; Rodgers JR Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043 [TBL] [Abstract][Full Text] [Related]
7. The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Ma YL; Weston SE; Whalley BJ; Stephens GJ Br J Pharmacol; 2008 May; 154(1):204-15. PubMed ID: 18311186 [TBL] [Abstract][Full Text] [Related]
8. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367 [TBL] [Abstract][Full Text] [Related]
9. Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Jarrett MM; Scantlebury J; Parker LA Physiol Behav; 2007 Feb; 90(2-3):425-30. PubMed ID: 17118412 [TBL] [Abstract][Full Text] [Related]
10. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Verty AN; Singh ME; McGregor IS; Mallet PE Psychopharmacology (Berl); 2003 Jul; 168(3):314-23. PubMed ID: 12700881 [TBL] [Abstract][Full Text] [Related]
11. Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. O'Brien LD; Wills KL; Segsworth B; Dashney B; Rock EM; Limebeer CL; Parker LA Pharmacol Biochem Behav; 2013 Jan; 103(3):597-602. PubMed ID: 23103902 [TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. McMahon LR Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389 [TBL] [Abstract][Full Text] [Related]
13. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722 [TBL] [Abstract][Full Text] [Related]
14. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444 [TBL] [Abstract][Full Text] [Related]
15. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509 [TBL] [Abstract][Full Text] [Related]
16. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction. Dhawan K; Kumar S; Sharma A J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005 [TBL] [Abstract][Full Text] [Related]
17. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Ko MC; Woods JH Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438 [TBL] [Abstract][Full Text] [Related]
18. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Vickers SP; Webster LJ; Wyatt A; Dourish CT; Kennett GA Psychopharmacology (Berl); 2003 Apr; 167(1):103-11. PubMed ID: 12632249 [TBL] [Abstract][Full Text] [Related]
19. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. Nakamura-Palacios EM; Winsauer PJ; Moerschbaecher JM Behav Pharmacol; 2000 Aug; 11(5):377-86. PubMed ID: 11103889 [TBL] [Abstract][Full Text] [Related]